The efficacy of albumin-globulin ratio to predict prognosis in cancer patients.
Document Type
Article
Publication Date
9-2023
Publication Title
International Journal of Clinical Oncology
Keywords
Cancer, Tumor, Prognosis, Biomarker, Oncology, Metastasis, Cancer treatment, Cancer diagnosis, Nutrition, Nutritional status, Immuno-oncology
ISSN
1437-7772
Volume
28
First Page
1101
Last Page
1111
Abstract
The goal of this systematic review was to identify all of the research within the last 10 years that investigated both the Albumin-Globulin Ratio (AGR) and outcomes of solid tumor cancer patients via quantitative prognostic variables. Multiple scientific databases were researched for journal articles that included keywords relating AGR to prognosis. Once isolated from the databases, the articles were de-duplicated and manually screened based on standardized inclusion/exclusion criteria in a blind format via Rayyan. The collective data were sorted by cancer type, corrected for population size, and used to calculate the average cut-off values for the most popular prognostic variables. In total, 18 independent types of cancer have been evaluated to see if AGR is a prognostic indicator based on multivariate analyses. The average cut-off value for AGR in overall survival was 1.356, while the average cut-off value for AGR in progression free survival was 1.292. AGR was found to be significantly associated with at least one prognostic variable in every type of cancer evaluated based on multivariate analyses. The ease of access and affordability of AGR makes it an invaluable tool applicable to nearly all patients. Overall, AGR is a proven prognostic variable that should always be considered in the evaluation of a solid tumor cancer patient's prognosis. Further research needs to be conducted studying the potential prognostic effect in more types of solid tumors.
NSUWorks Citation
Roberts, Will S.; Delladio, William; Price, Shawn; Murawski, Alec; and Nguyen, Hoang, "The efficacy of albumin-globulin ratio to predict prognosis in cancer patients." (2023). HPD Articles. 377.
https://nsuworks.nova.edu/hpd_facarticles/377
ORCID ID
DOI
10.1007/s10147-023-02380-4
Copyright
© The Author(s) under exclusive licence to Japan Society of Clinical Oncology 2023